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Abstract
Background: Lithogenic bile is the major cause of cholesterol gallstone, but its pathogenesis is not well
understood. The hypersecretion of biliary cholesterol is believed to be an important cause of lithogenic bile. Sterol
Carrier Protein 2 (SCP2) participates in cholesterol trafficking and lipid metabolism in hepatocytes and may play a
key role in cholesterol gallstone formation.
Methods: 21 cholesterol gallstone genealogies were studied to investigate the expression of SCP2 gene in liver
tissue of hereditary and non-hereditary cholesterol gallstone patients as well as non-gallstone patients. The mRNA
expression of liver SCP2 in 28 hereditary patients, 30 non-hereditary cholesterol gallstone patients and 32 non-
gallstone patients was measured by Reverse Transcription Polymerase Chain Reaction (RT-PCR). The protein
expression of liver SCP2 was also detected in all the patients by Western blotting. At the same time, the bile was
also analyzed with biochemical techniques and the Cholesterol Saturation Index (CSI) was calculated.
Results: The mRNA and protein expression of SCP2 was significantly increased in cholesterol gallstone patients
compared to those of non-gallstone patients. Moreover, SCP2 was expressed at higher levels in hereditary
cholesterol gallstone patients than that of non-hereditary cholesterol gallstone patients. There was significant
difference observed in CSI between cholesterol gallstone patients and non-gallstone patients, but not in CSI
between hereditary and non-hereditary cholesterol gallstone patients.
Conclusions: SCP2 was overexpressed in hereditary cholesterol gallstone patients compared to non-hereditary
cholesterol gallstone patients. This finding indicated that SCP2 might be one of the genetic factors contributing to
cholesterol gallstone formation, which was always accompanied by the increase of bile lithogenicity.
Background
Hypersecretion of cholesterol in bile, leading to the for-
mation of lithogenic bile, is believed to be the major
cause of cholesterol gallstones [1]. Sterol carrier protein
2 (SCP2), also called nonspecific lipid transfer protein, is
a 13.2 KD base protein and exists in peroxisome, mito-
chondria, endoplasmic reticulum and cytoplasm [2-4].
As a moderating factor of cholesterol metabolism, it is
involved in the biosynthesis of cholesterol [5-7] and the
transformation of cholesterol to bile acid [8,9], choles-
teryl ester [10] and sterols [11]. As a transporting tool,
on the other hand, this protein participates in the trans-
portation of cholesterol inside the cell and through the
cytoplasm membrane [12,13] as well as the rapid trans-
portation of the newly synthesized cholesterol from
endoplasmic reticulum into the bile without the inter-
vention of cytomicrotubule system and Golgi bodies
[14]. Hence, hypersecretion of biliary cholesterol with
the formation of lithogenic bile may explain the forma-
tion mechanism of the cholesterol stones in the
gallbladder.
We have found some patients with gallstone to also
have familial backgrounds of the same condition. In
such cases, individuals were more susceptible to choles-
terol stone formation than those individuals lacking this
familial background. Therefore, in this study, we have
enrolled patients with a familial background in order to
determine if differences in SCP2 expression levels and
the bile CSI between hereditary and non-hereditary
cholesterol gallstone patients exist.
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Methods
We have accumulated 21 cholesterol gallstone families and
undertook a study to investigate the expression of SCP2 in
liver tissue of hereditary and non-hereditary cholesterol
gallstone patients as well as non-gallstone patients by
using reverse transcription-polymerase chain reaction and
Western Blotting. The bile was also analyzed by means of
biochemical techniques and Cholesterol Saturation Index
(CSI) was calculated at the same time.
Case Selections
Hereditary cholesterol gallstone group
Patients with cholesterol stones in the gallbladder, cho-
lesterol contents >50% and with a familial background.
The criterion of familial background is such that there
are no less than two patients who are in different gen-
erations of consanguinity in one family.
Non-hereditary cholesterol gallstone group
Patients with cholesterol stones in the gallbladder, cho-
lesterol contents >50%, but without a familial
background.
Control group
Patients with primary intrahepatic cholangiolithiasis and
cholesterol contents <20%; patients with peptic ulcer,
cancer of the stomach or of the colon in whom no gall-
stones are verified by ultrasound diagnosis.
Exclusion criteria
Patients with diabetes or with other endocrine metabo-
lism disorders; obese individuals; and patients with
other diseases of the liver and the gallbladder.
All patients were admitted to and had operations at
Tianjin Nankai Hospital between August 2003 and
August 2008. Hereditary gallstone group consisted of 28
patients with cholesterol stones in the gallbladder, 15
females and 13 males, aging between 25-80 years. The
stones appeared yellow or light yellow in color, with
smooth or nodular surfaces. Non-hereditary cholesterol
gallstone group consisted of 30 patients with cholesterol
stones in the gallbladder, 16 females and 14 males, aging
between 20-80 years old. The control group consisted of
32 patients, including 16 females and 16 males, aging
between 15-78 years old. Of the 32 patients in the control
group, 8 patients suffered from primary hepatocholedo-
colithiasis with brown stones which were pigment stones,
5 patients were diagnosed with gastric cancer, 11 patients
with non-cholesterol polyp in the gallbladder, and 8 with
pancreatic cancer. There were no significant differences
between the three groups when compared by the age and
the body mass index (P > 0.05).
Bile and Liver Sampling
Patients fasted for 12 hours before the operation and
general anaesthesia was administered. A liver specimen
of 50 mg was obtained and bile collected from
gallbladder. Bile was kept at -20°C while liver tissues
were stored at -70°C until it was processed. Biopsies
were permitted by Hospital Ethics Committee and the
consents obtained from the patients and family
members.
Identification of Cholesterol Stones
Stones obtained during the operation were rinsed with
water and put in the dryer until a constant weight was
obtained. Then the stones were ground and dried naturally
for 12 hours. A sample of 10 mg gallstone powder was
weighed and dissolved in 5 ml anhydrous alcohol, stirred
for 3 minutes, and centrifuged at 3000 rpm for 5 minutes.
The supernatant was collected for further analysis.
Another 10 mg sample was accurately weighed, dissolved
in 5 ml chloroform, stirred for 3 minutes, centrifuged at
3000 rpm for 5 minutes, and the supernatant was collected
for analysis. The cholesterol and calcium bilirubinate were
measured by enzyme method. The ratio of cholesterol
content to calcium bilirubinate content was calculated and
used for sample classification. Samples with a ratio >0.5
were classified as cholesterol stones, and those with a ratio
<0.5 as pigment stones [15].
Reverse-Transcription Polymerase Chain Reaction
Total RNA was prepared from liver tissue by using Trizol
method and 1 μg RNA was reverse-transcribed by using
random primer hexamers. Reverse-transcription polymer-
ase chain reaction (RT-PCR) was performed by using
primers based on the human SCP2 cDNA sequence
[M55421.1] from Genebank. For SCP2, upper Primer is 5’-
ATGGGTTTTCCGGAAGCCGCCAGTT, lower primer is
5’-TCAGAGCTTA GCGTTGCCTGGCTG, and the PCR
fragment was a product of 432 bp. For b2-Microglobulin,
upper Primer is 5’-ATGCCTGCCGTGTGAACCATGT,
lower primer is 5’-AGAGCTACCTGTGGAGCAACCT,
and the PCR fragment was a product of 285 bp. SCP2 and
b2-Microglobulin genes were amplified at the same time,
under the same conditions. PCR was carried out as fol-
lows: one cycle of 94°C for 3 min, and 22 cycles of 94°C
for 1 min, 58°C for 1 min, 72°C for 1 min, and one cycle
of 72°C for 3 min. After electrophoresis, PCR products
were quantified by the Gene Genius Gel Documentation
and Analysis System, and SCP2 expression level was nor-
malized to b2-Microglobulin level.
Western Blot
The tissues were lysed with the lysis buffer (50 mM Tris
PH7.4, 150 mM NaCl, 0.5% Triton X-100, 1 mM EDTA,
1 mM PMSF). Total protein was separated by 12%
sodium dodecyl sulfate polyacrylamide gel electrophor-
esis and electrophoretically transferred onto polyvinyli-
dene difuoride membrane (Millipore, Bedford, MA,
USA). After blocking non-specific binding sites with 5%
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non-fat milk, the membrane was incubated with primary
antibodies for 1 h at room temperature. After washing,
the blots were incubated with horseradish peroxidase-
conjugated anti-mouse or anti-rabbit IgG, and immu-
noreactive bands were visualized with Western Blotting
Luminol Reagent kit (Santa Cruz Biotechnology Inc).
Densitometric analysis was used to select the contour of
the band, subtract the background and calculate the
density. The primary antibodies used in this experiment
were as follows: anti-SCP2 antibody (kindly provided by
Dr Schroeder, Texas A&M University, 1:1000 dilution)
and anti-GAPDH antibody (Santa Cruz Biotechnology,
1:2000 dilution).
Bile Biochemical Analyses
The concentrations of biliary cholesterol, phospholipids,
and total bile acids were measured using enzymatic kits
(Zhongsheng Bioengineering High-Tech Co.).
Data Analysis
All data were expressed as mean ± standard deviation.
Difference between control and experimental groups
were evaluated by one-way analysis of variance
(ANOVA). P < 0.05 was considered statistically signifi-
cant (a = 0.05).
Results
The mRNA and protein expression of SCP2 in hereditary
gallstone group, non-hereditary gallstone group and
control group
We detected mRNA and protein expression of SCP2,
the main cholesterol transporter and mediator in hepa-
tocytes. As shown in Figure 1, SCP2 mRNA was
expressed at higher levels in hereditary cholesterol
gallstone patients compared to those of non-hereditary
cholesterol gallstone patients. The expression of SCP2
mRNA in hereditary as well as non-hereditary choles-
terol gallstone patients was significantly higher than
that of the control group. Three groups were com-
pared by one way analysis of variance, and F = 11.089,
P < 0.05.
We analyzed the expression of SCP2 in all samples by
Western blot and GAPDH was used as the internal con-
trol. Results were shown in Figure 2 as SCP2/GAPDH
ratio. Consistent with the expression level of SCP2
mRNA, SCP2 protein was expressed at higher levels in
hereditary cholesterol gallstone patients than in non-
hereditary cholesterol gallstone patients, P < 0.05. SCP2
protein relative levels in hereditary and non-hereditary
cholesterol gallstone patients were 1.5898 ± 0.0316 and
1.3032 ± 0.0664, respectively, which were both higher
than that in control group, 0.7637 ± 0.0258, P < 0.05.
Three groups were compared by one way analysis of
variance, F = 1084.98, P < 0.05.
Figure 1 The mRNA levels of SCP2 in hereditary gallstone
group, non-hereditary gallstone group and control group. SCP2
mRNA expression was assessed by semi quantitative RT-PCR and
shown as fold change after normalized to b2-Microglobulin levels.
SCP2 mRNA was expressed at higher levels in hereditary cholesterol
gallstone patients than in non-hereditary cholesterol gallstone
patients, P < 0.05. The mRNA expression of SCP2 in hereditary, and
non-hereditary cholesterol gallstone patients were 0.8908 ± 0.1649,
0.7503 ± 0.1004 respectively, which were both higher than that in
control group,0.5205 ± 0.1900, P < 0.05. The data was analyzed by
one way analysis of variance, and F = 11.089, P < 0.05.
Figure 2 The protein levels of SCP2 in hereditary gallstone
group, non-hereditary gallstone group and control group. All
samples were analyzed by Western blot using anti-SCP2 antibody,
and GAPDH was used as the internal control. Results were shown as
SCP2/GAPDH ratio in arbitrary densitometric units representing SCP2
protein relative levels. Lane ① and ② are from control group, Lane
③ and ④ from non-hereditary group, and Lane ⑤ and ⑥ from
hereditary group. SCP2 protein was expressed at higher level in
hereditary cholesterol gallstone patients than that in non-hereditary
cholesterol gallstone patients, and the difference was statistically
significant, P < 0.05. SCP2/GAPDH ratios in hereditary, and non-
hereditary cholesterol gallstone patients were 1.5898 ± 0.0316,
1.3032 ± 0.0664 respectively, which were both higher than that in
control group,0.7637 ± 0.0258, P < 0.05.
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Changes of bile components and lithogenicity between
hereditary, non-hereditary cholesterol gallstone patients
and control groups
The concentrations of cholesterol, phospholipids and
bile acids in gallbladder bile were obtained and the CSI
was calculated using the Carey table. As shown in
Table 1 and Figure 3, we have found cholesterol in her-
editary and non-hereditary cholesterol gallstone patients
to be higher than that in control group. Total bile acids
in hereditary and non-hereditary cholesterol gallstone
patients were both lower than that in control group.
Additionally, no significant difference in Phospholipids
between the three groups was observed.
CSIs in hereditary and non-hereditary cholesterol gall-
stone patients were both higher than that in control
group, P < 0.05; however, no significant difference was
observed in CSIs between hereditary and non-hereditary
cholesterol gallstone patients. Three groups were com-
pared by one way analysis of variance, F = 49.166, P < 0.05.
Discussion
Cholesterol gallstone formation is a complicated process
involving a variety of factors. The abnormal metabolism
of liver cholesterol and supersaturation of bile cholesterol
are the major causes of stone formation. In recent years,
some scholars have finished a series of epidemiological
studies in high-risk populations about cholelithiasis
[16-18] and have made some interesting findings. The
gallstone disease is a genetic disease involving multiple
genes and having the genetic characteristic of autosomal
dominant delay. Gallstone formation is caused by com-
mon genetic factors along with multiple environmental
factors. Interactions between related genes and environ-
mental factors play an important role in the pathogenesis
of gallstone formation.
Ito, et al [19]conducted an analysis of three regulatory
enzymes in the cholesterol metabolism, as well as cho-
lesterol levels and sterol carrier protein 2/nonspecific
lipid transfer protein (SCP2/nsLTP) levels by using liver
biopsy samples of Japanese patients who had cholesterol
gallstones and underwent cholecystectomy. His results
suggest that intracellular cholesterol transport is
enhanced in patients with cholesterol gallstones. Animal
experiments confirmed SCP2 was an essential factor in
the transportation of newly synthesized cholesterol into
bile; rapidly transfering cholesterol from endoplasmic
reticulum directly into the bile without the involvement
of the cellular microtubule system and the Golgi [20].
Fuchs, et al [11,21] observed the phenomenon in the
stone susceptible mice where SCP2 protein and SCP2
mRNA arose at the same time and thought that the
transcriptional upregulation of SCP2 led to the higher
level of SCP2 in liver cell, then increasing bile choles-
terol and promoting the gallstone formation. Further
studies on susceptible mice found that Lith 1 gene
might result in overexpression of SCP2 mRNA during
the formation of gallstones.
In our previous studies [22,23], we have found SCP2
mRNA to be overexpressed in cholesterol gallstone
Table 1 The concentrations of Cholesterol, Total Bile Acids and Phospholipids in gallbladder bile
group Cholesterol a (mmol/L) Total Bile Acids b(mmol/L) Phospholipids c (mmol/L) CSI d
control group 3.0620 ± 0.7053 14.6700 ± 1.3316 8.4880 ± 0.8190 0.7342 ± 0.1550
non-hereditary group 3.8333 ± 0.7217** 11.1667 ± 1.2010** 8.8933 ± 1.1162** 1.5190 ± 0.2715**
hereditary group 3.9200 ± 0.7229* 11.0900 ± 1.2038* 8.8600 ± 0.8050* 1.5810 ± 0.2400*
a*compared with control group P < 0.05, compared with non-hereditary group P > 0.05; **compared with control group P < 0.05.
b*compared with control group P < 0.05, compared with non-hereditary group P > 0.05; **compared with control group P < 0.05.
c*compared with control group P > 0.05, compared with non-hereditary group P > 0.05; **compared with control group P > 0.05.
d*compared with control group P < 0.05, compared with non-hereditary group P > 0.05; **compared with control group P < 0.05.
Figure 3 Changes of gallbladder bile Cholesterol, Total Bile
Acids and Phospholipids in hereditary, non-hereditary
cholesterol gallstone patients and control group. Bile cholesterol
in hereditary, and non-hereditary cholesterol gallstone patients were
both higher than that in control group, P < 0.05. But there was no
significant difference in bile cholesterol level between hereditary
and non-hereditary cholesterol gallstone patients. Three groups
were compared by one way analysis of variance, F = 84.230, P <
0.05. Total bile acids level in hereditary and non-hereditary
cholesterol gallstone patients were both lower than that in control
group, P < 0.05. There was no significant difference in Total bile
acids level between hereditary and non-hereditary cholesterol
gallstone patients. Three groups were also analyzed by one way
analysis of variance, F = 17.382, P < 0.05. There were no significant
differences in Phospholipids level between three groups. Three
groups were also compared by one way analysis of variance,
F = 0.492, P > 0.05.
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patients compared to the control group (P < 0.05),
which was consistent with other studies [11,19,21].
Interestingly, we have also found that some patients
with gallstone gathered in some families and the indivi-
duals with a familial background were more susceptible
to form cholesterol stones than those without a familial
background. Based on this initial finding, heredity could
be another factor contributing to cholesterol gallstone
formation. To elucidate the possibility, we have enrolled
into our research patients with a familial background
and increased the number of cases in order to deter-
mine whether or not the differences in SCP2 expression
and the bile CSI can be observed between hereditary
and non-hereditary cholesterol gallstone patients.
We have found mRNA and protein expression of
SCP2 in hereditary cholesterol gallstone group to be sig-
nificantly higher than that of non-hereditary cholesterol
gallstone group, (P < 0.05). In addition, we have also
found mRNA and protein expression of SCP2 to be
higher in non-hereditary cholesterol gallstone group
than that of control group. Compared with the study of
Ito et al, we have observed higher expression of SCP2 in
hereditary cholesterol gallstone group than that of non-
hereditary cholesterol gallstone group. The different
levels of SCP2 expression between hereditary and non-
hereditary cholesterol gallstone groups indicatethat
SCP2 as one of the genetic factors in the formation of
cholesterol gallstones. An overexpression of SCP2 in the
liver may lead to higher concentration of cholesterol in
the bile, causing bile lithogenicity to exceed the normal
borderline, which could cause the cholesterol crystals to
separate out and form the initial stones in the bile. The
increased SCP2 levels can also accelerate the transporta-
tion of cholesterol inside hepatocytes and the excretion
across the membrane of liver cells. There are also some
other possibilities that SCP2, as a moderator, may regu-
late the metabolic process of cholesterol, such as
HMGCR, 7alpha-hydroxylase and ACAT. We have
found lithogenicity of bile in cholesterol gallstone
patients to be higher than that of control group, but
there was no significance difference in the lithogenicity
of bile between hereditary and non-hereditary choles-
terol gallstone groups. So the formation of gallstones
was always accompanied by the higher lithogenicity of
bile.
Beyond the relationship between SCP2 expression and
cholesterol gallstone formation, the underlying molecu-
lar mechanisms are still unclear, especially those
involved in the relationship between SCP2 and familial
backgrounds.
Conclusions
SCP2 may be a genetic factor influencing the suscept-
ibility to the formation of gallstones under the same life
environment, and overexpression of SCP2 could be one
of the important causes of cholesterol gallstones. The
formation of gallstones is always accompanied by the
increase in bile lithogenicity, which is not heredity-
dependent.
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